BACKGROUND: Neuroprotective effects of lithium (Li) have been well documented in tissue cultures and animal models, whereas human data continue to be limited. Previous studies investigating the association between Li treatment and brain N-acetylaspartate (NAA), a putative neuronal marker, showed mixed results because of methodological heterogeneity. METHODS: To investigate the effects of Li on prefrontal cortex NAA levels, we compared patients with bipolar disorder from specialized Li clinics in Berlin and Halifax with at least 2 years of ongoing Li treatment (Li group), patients with lifetime Li exposure of less than 3 months more than 2 years ago (non-Li group) and healthy controls. Participants in both patient groups had at least 10 years of illness and 5 episodes. We measured left prefrontal NAA levels using 1.5-T magnetic resonance spectroscopy. RESULTS: We enrolled 27 participants in the Li, 16 in the non-Li and 21 in the healthy control groups. The non-Li group had lower prefrontal NAA levels than the Li group (t41 = -3.44, corrected p < 0.01) or control participants (t35 = -2.91, corrected p < 0.05), who did not differ from the Li group (t46 = -0.14, p = 0.89). The same pattern of prefrontal NAA differences was replicated in both sites. In addition, there was a negative correlation between prefrontal NAA and duration of illness in the non-Li group (r = -0.60, p = 0.019) but not in the Li group (r = 0.07, p = 0.74). LIMITATIONS: Study limitations include the crosssectional design and exposure to other medications. CONCLUSION: Whereas patients with bipolar disorder, substantial illness burden and limited lifetime Li exposure had significantly lower prefrontal NAA levels than controls, Li-treated patients with similar illness burden showed prefrontal NAA levels comparable to those of healthy controls. These findings provide indirect support for neuroprotective effects of Li and for negative effects of illness burden on prefrontal NAA levels in patients with bipolar disorder.
BACKGROUND: Neuroprotective effects of lithium (Li) have been well documented in tissue cultures and animal models, whereas human data continue to be limited. Previous studies investigating the association between Li treatment and brain N-acetylaspartate (NAA), a putative neuronal marker, showed mixed results because of methodological heterogeneity. METHODS: To investigate the effects of Li on prefrontal cortex NAA levels, we compared patients with bipolar disorder from specialized Li clinics in Berlin and Halifax with at least 2 years of ongoing Li treatment (Li group), patients with lifetime Li exposure of less than 3 months more than 2 years ago (non-Li group) and healthy controls. Participants in both patient groups had at least 10 years of illness and 5 episodes. We measured left prefrontal NAA levels using 1.5-T magnetic resonance spectroscopy. RESULTS: We enrolled 27 participants in the Li, 16 in the non-Li and 21 in the healthy control groups. The non-Li group had lower prefrontal NAA levels than the Li group (t41 = -3.44, corrected p < 0.01) or control participants (t35 = -2.91, corrected p < 0.05), who did not differ from the Li group (t46 = -0.14, p = 0.89). The same pattern of prefrontal NAA differences was replicated in both sites. In addition, there was a negative correlation between prefrontal NAA and duration of illness in the non-Li group (r = -0.60, p = 0.019) but not in the Li group (r = 0.07, p = 0.74). LIMITATIONS: Study limitations include the crosssectional design and exposure to other medications. CONCLUSION: Whereas patients with bipolar disorder, substantial illness burden and limited lifetime Li exposure had significantly lower prefrontal NAA levels than controls, Li-treated patients with similar illness burden showed prefrontal NAA levels comparable to those of healthy controls. These findings provide indirect support for neuroprotective effects of Li and for negative effects of illness burden on prefrontal NAA levels in patients with bipolar disorder.
Authors: John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri Journal: Prog Neurobiol Date: 2007-01-05 Impact factor: 11.685
Authors: Jose Antonio de M S Amaral; Renata S Tamada; Cilly K Issler; Sheila C Caetano; Giovanni G Cerri; Claudio C de Castro; Beny Lafer Journal: Hum Psychopharmacol Date: 2006-06 Impact factor: 1.672
Authors: Kim A Gallelli; Christopher M Wagner; Asya Karchemskiy; Meghan Howe; Daniel Spielman; Allan Reiss; Kiki D Chang Journal: Bipolar Disord Date: 2005-12 Impact factor: 6.744
Authors: Roberto B Sassi; Jeffrey A Stanley; David Axelson; Paolo Brambilla; Mark A Nicoletti; Matcheri S Keshavan; Renato T Ramos; Neal Ryan; Boris Birmaher; Jair C Soares Journal: Am J Psychiatry Date: 2005-11 Impact factor: 18.112
Authors: Manpreet K Singh; Booil Jo; Nancy E Adleman; Meghan Howe; Layla Bararpour; Ryan G Kelley; Daniel Spielman; Kiki D Chang Journal: Psychiatry Res Date: 2013-09-09 Impact factor: 3.222
Authors: Paul E Croarkin; M Albert Thomas; John D Port; Joshua M Baruth; Doo-Sup Choi; Osama A Abulseoud; Mark A Frye Journal: Bipolar Disord Date: 2014-12-12 Impact factor: 6.744
Authors: Joanne H Huang; Shaunna S Berkovitch; Jonathan Iaconelli; Bradley Watmuff; Hyoungjun Park; Shrikanta Chattopadhyay; Donna McPhie; Dost Öngür; Bruce M Cohen; Clary B Clish; Rakesh Karmacharya Journal: Mol Neuropsychiatry Date: 2016-06-24
Authors: Rafael T de Sousa; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji Journal: Expert Opin Ther Targets Date: 2014-07-24 Impact factor: 6.902
Authors: Tomas Hajek; Cynthia Calkin; Ryan Blagdon; Claire Slaney; Rudolf Uher; Martin Alda Journal: Neuropsychopharmacology Date: 2014-06-19 Impact factor: 7.853